20 types of hormonal disease system all ages group disease treatment investigation finding differential diagnosis contraindications ICU and OPD and blood RBC WBC platelet nutrition flute of diagnosis summary

Checking Date & Time
Reading File
This is a very broad, comprehensive request covering 20 hormonal diseases across all ages. Given the budget constraints, I'll use parallel subagents to research key hormonal diseases, then synthesize a comprehensive reference document.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Now I'll synthesize the comprehensive reference document from medical library findings and expert clinical knowledge:

πŸ₯ 20 Hormonal (Endocrine) Diseases β€” Comprehensive Clinical Reference

All Age Groups | Treatment | Investigations | Findings | DDx | ICU/OPD | CBC | Nutrition


πŸ“‹ MASTER OVERVIEW TABLE

#DiseaseGland/HormoneAge Group Most AffectedSetting
1Type 1 Diabetes MellitusPancreas / Insulin ↓Children, Young AdultsOPD/ICU
2Type 2 Diabetes MellitusPancreas / Insulin resistanceAdults >40, ObeseOPD
3HypothyroidismThyroid / T3,T4 ↓All ages (F>M)OPD
4Hyperthyroidism / Graves'Thyroid / T3,T4 ↑Young-Middle-aged FOPD/ICU
5Cushing's SyndromeAdrenal / Cortisol ↑Adults 20–50OPD/ICU
6Addison's DiseaseAdrenal / Cortisol ↓Adults 30–50OPD/ICU
7Congenital HypothyroidismThyroid / T4 ↓NeonatesNICU/OPD
8Congenital Adrenal Hyperplasia (CAH)Adrenal / Cortisol,Aldosterone ↓Neonates, InfantsNICU/OPD
9Diabetes InsipidusPituitary / ADH ↓All agesOPD/ICU
10SIADHPituitary / ADH ↑Adults, ElderlyICU/OPD
11AcromegalyPituitary / GH ↑Adults 30–50OPD
12GigantismPituitary / GH ↑Children/AdolescentsOPD
13PheochromocytomaAdrenal medulla / Catecholamines ↑Adults 30–50OPD/ICU
14Primary Hyperaldosteronism (Conn's)Adrenal / Aldosterone ↑Adults 30–60OPD
15HypoparathyroidismParathyroid / PTH ↓Adults, Post-surgicalOPD/ICU
16HyperparathyroidismParathyroid / PTH ↑Adults >50, F>MOPD
17Polycystic Ovary Syndrome (PCOS)Ovary / Androgens ↑, FSH/LH imbalanceReproductive age FOPD
18Precocious PubertyGonads / Sex hormones ↑ earlyChildren <8F, <9MOPD
19Growth Hormone Deficiency (GHD)Pituitary / GH ↓Children, AdultsOPD
20ProlactinomaPituitary / Prolactin ↑Young adults, F>MOPD

1️⃣ TYPE 1 DIABETES MELLITUS (T1DM)

Pathophysiology

Autoimmune destruction of pancreatic Ξ²-cells β†’ absolute insulin deficiency β†’ hyperglycemia, ketoacidosis

Age Group

Children (peak 5–7 y, 11–14 y), young adults; any age possible

Clinical Findings

  • Classic triad: Polyuria, Polydipsia, Polyphagia + weight loss
  • Diabetic Ketoacidosis (DKA): Kussmaul breathing, fruity breath, vomiting, altered consciousness
  • Blurred vision, fatigue, recurrent infections

Investigations

TestFinding
Fasting plasma glucoseβ‰₯126 mg/dL
2-hr OGTTβ‰₯200 mg/dL
Random glucoseβ‰₯200 mg/dL + symptoms
HbA1cβ‰₯6.5%
C-peptideVery low/undetectable
Anti-GAD65, anti-IA2, anti-islet antibodiesPositive (confirm autoimmune)
UrinalysisGlucose + ketones
Arterial blood gas (DKA)Metabolic acidosis, pH <7.3
Serum electrolytes↓K⁺ (total body deficit despite initial hyperkalemia)

Blood Count (CBC)

  • RBC: Normal or ↓ (chronic disease anemia)
  • WBC: ↑ Leukocytosis in DKA (stress response/infection)
  • Platelets: Usually normal; ↑ (reactive thrombocytosis) in poor control

Treatment

SettingRegimen
OPDBasal-bolus insulin (long-acting: glargine/detemir + rapid-acting: lispro/aspart), carb counting, CGM, HbA1c target <7%
ICU/DKAIV regular insulin 0.1 U/kg/hr, IV fluids (0.9% NaCl), K⁺ replacement (add K if K⁺ <5.5 mEq/L), bicarb if pH <6.9
PediatricWeight-based dosing; puberty increases insulin resistance

Nutrition

  • Carbohydrate counting (45–60g/meal adults)
  • Low glycemic index foods; avoid concentrated sweets
  • Regular meal timing; protein-adequate diet

Differential Diagnosis

  • Type 2 DM (MODY), Maturity-Onset Diabetes of the Young (MODY)
  • Pancreatogenic diabetes (Type 3c)
  • DKA vs Hyperosmolar Hyperglycemic State (HHS)
  • Drug-induced hyperglycemia (steroids)

Contraindications

  • Metformin: contraindicated in T1DM as monotherapy
  • Thiazolidinediones: not indicated in T1DM
  • Sulfonylureas: avoid in T1DM

ICU Indications

DKA (pH <7.1, altered consciousness), severe hypoglycemia, sepsis

2️⃣ TYPE 2 DIABETES MELLITUS (T2DM)

Pathophysiology

Insulin resistance + progressive Ξ²-cell failure β†’ relative insulin deficiency

Age Group

Adults >40 (increasingly adolescents/obese youth); gestational DM in pregnancy

Clinical Findings

  • Often asymptomatic early; detected on screening
  • Polyuria, polydipsia, fatigue, blurred vision, slow-healing wounds
  • Acanthosis nigricans (insulin resistance skin sign)
  • Hyperosmolar Hyperglycemic State (HHS): extreme hyperglycemia, dehydration, altered consciousness β€” no ketones

Investigations

Same glucose/HbA1c thresholds as T1DM, PLUS:
TestFinding
Fasting insulin / HOMA-IRElevated (insulin resistance)
C-peptideNormal or elevated
Lipid panel↑Triglycerides, ↓HDL (metabolic syndrome)
MicroalbuminuriaEarly nephropathy marker
Serum creatinine/eGFRRenal function assessment
Liver enzymesFatty liver (NAFLD common)

Blood Count (CBC)

  • RBC: ↓ Normocytic anemia (CKD-related in advanced disease)
  • WBC: Normal or mildly elevated
  • Platelets: Often normal; ↑ in obesity/inflammation

Treatment

StepAgent
First-lineMetformin + lifestyle modification
Add-onGLP-1 agonists (semaglutide, liraglutide) β€” esp. with CVD/obesity
SGLT-2 inhibitors(empagliflozin) β€” heart failure/CKD benefit
DPP-4 inhibitorsSitagliptin β€” weight neutral
SulfonylureasGlipizide β€” low cost, risk of hypoglycemia
InsulinBasal insulin if HbA1c >10% or symptomatic

Nutrition

  • Caloric deficit for weight loss (500–750 kcal/day deficit)
  • Mediterranean or DASH diet preferred
  • Fiber β‰₯25g/day; limit refined carbs, saturated fat, sugar-sweetened beverages

Differential Diagnosis

  • T1DM (LADA β€” Latent Autoimmune Diabetes of Adults)
  • MODY (monogenic; family history, young age)
  • Cushing's syndrome (secondary DM)
  • Acromegaly, glucagonoma

Contraindications

  • Metformin: contraindicated if eGFR <30, severe liver disease, IV contrast (hold 48h), active alcoholism
  • SGLT-2i: contraindicated if eGFR <20 (for glycemic purpose), T1DM (risk euDKA), recurrent UTI/genital infections
  • GLP-1 agonists: contraindicated with personal/family history of medullary thyroid cancer/MEN2

3️⃣ HYPOTHYROIDISM

Pathophysiology

Insufficient thyroid hormone (T3/T4) β†’ slowed metabolism

Age Group

  • Congenital: Neonates (cretinism if untreated)
  • Hashimoto's thyroiditis: Adolescents, adults (F>>M)
  • Primary atrophic: Elderly
  • Iatrogenic: Post-thyroidectomy, post-radioiodine

Clinical Findings

  • Cold intolerance, weight gain, constipation, fatigue, depression
  • Bradycardia, delayed tendon reflexes ("hung-up reflex")
  • Dry skin, hair loss, periorbital puffiness (myxedema)
  • Goiter (Hashimoto's), hoarse voice, macroglossia
  • Myxedema coma (severe): hypothermia, hypotension, hypoventilation, coma

Investigations

TestHypothyroidism Finding
TSH↑↑↑ (primary); ↓ (secondary/tertiary)
Free T4↓
Free T3↓
Anti-TPO antibodiesPositive (Hashimoto's)
Anti-thyroglobulin AbPositive (Hashimoto's)
Lipid panel↑ Total cholesterol, ↑ LDL
CK↑ (myopathy)
Na⁺↓ (dilutional hyponatremia)
ECGBradycardia, low voltage, T-wave flattening

Blood Count (CBC)

  • RBC: ↓ Macrocytic anemia (↓ EPO, B12/folate deficiency association), or normocytic
  • WBC: Usually normal
  • Platelets: May be ↓ (thrombocytopenia, rare); ↑ bleeding time

Treatment

SettingTreatment
OPDLevothyroxine (T4): start 1.6 mcg/kg/day (lower dose in elderly/CAD); adjust by TSH every 6 weeks
Myxedema Coma (ICU)IV levothyroxine 200–500 mcg bolus + IV T3 + IV hydrocortisone (until adrenal co-involvement excluded) + rewarming + respiratory support
CongenitalLevothyroxine ASAP (within 2 weeks of birth)
PregnancyHigher LT4 requirement; TSH target 0.1–2.5 mIU/L

Nutrition

  • Adequate iodine (iodized salt, seafood) unless Hashimoto's
  • Selenium supplementation may help Hashimoto's
  • Take levothyroxine 30–60 min before food; avoid calcium/iron within 4h

Differential Diagnosis

  • Depression, CFS, anemia
  • Nephrotic syndrome (edema)
  • Lipid disorder (hypercholesterolemia)
  • Hypopituitarism (secondary hypothyroidism)

Contraindications

  • Untreated adrenal insufficiency: do NOT start levothyroxine before cortisol replacement (precipitates adrenal crisis)
  • Calcium, iron, cholestyramine: reduce LT4 absorption (separate by 4h)

4️⃣ HYPERTHYROIDISM / GRAVES' DISEASE

Pathophysiology

Excess T3/T4 β†’ hypermetabolism. Graves' = TSI (TSH receptor stimulating antibodies)

Age Group

Young to middle-aged adults; F:M = 7–10:1; can occur in pregnancy (Graves')

Clinical Findings

  • Heat intolerance, weight loss despite good appetite, palpitations, tremor
  • Tachycardia, atrial fibrillation, hypertension (widened pulse pressure)
  • Exophthalmos (proptosis), lid lag, lid retraction β€” Graves' specific
  • Pretibial myxedema, thyroid acropachy β€” Graves' specific
  • Thyroid bruit, diffuse goiter
  • Thyroid storm: HR >140, hyperpyrexia >40Β°C, confusion/coma β€” ICU emergency

Investigations

TestFinding
TSH↓↓↓ (suppressed)
Free T4 / Free T3↑↑
TSI (TSH receptor antibodies)Positive in Graves'
Thyroid uptake scan↑ Diffuse uptake (Graves'); focal hot nodule (toxic adenoma)
CBCNeutropenia (if on antithyroid drugs)
LFTs↑ (Graves' hepatopathy)

Blood Count (CBC)

  • RBC: Normocytic anemia (increased plasma volume effect)
  • WBC: ↓ Neutropenia (risk with propylthiouracil/methimazole β€” check BEFORE antithyroid therapy)
  • Platelets: May be ↓ (immune thrombocytopenia in Graves')

Treatment

OptionDetails
Antithyroid drugsMethimazole (preferred) or PTU (preferred in 1st trimester); 12–18 month course; check CBC (agranulocytosis risk)
Radioiodine (RAI) ΒΉΒ³ΒΉIDefinitive; not in pregnancy/active ophthalmopathy
SurgeryNear-total thyroidectomy (large goiter, compressive symptoms, cancer concern)
Beta-blockersPropranolol/atenolol for symptomatic control (tremor, palpitations) β€” use until euthyroid
Thyroid storm (ICU)PTU + iodine (Lugol's, 1h after PTU) + propranolol IV + hydrocortisone + cooling + IV fluids

Nutrition

  • High-calorie, high-protein diet (hypermetabolic state)
  • Avoid iodine-rich foods/supplements (seaweed, kelp) if on antithyroid therapy
  • Calcium/vitamin D supplementation post-thyroidectomy

Contraindications

  • Methimazole: teratogenic in 1st trimester (use PTU instead)
  • RAI: absolute contraindication in pregnancy and breastfeeding
  • Iodine (Lugol's): never give BEFORE antithyroid drugs (Jod-Basedow worsening)

ICU Indications

Thyroid storm, severe cardiac arrhythmia, heart failure

5️⃣ CUSHING'S SYNDROME

Pathophysiology

Chronic excess cortisol: ACTH-dependent (pituitary adenoma = Cushing's disease 70%; ectopic ACTH) or ACTH-independent (adrenal adenoma/carcinoma, exogenous steroids)

Age Group

Adults 20–50 years; F>M; exogenous (iatrogenic) = most common cause overall

Clinical Findings

  • Central obesity (buffalo hump, moon face, supraclavicular fat pads)
  • Purple striae >1 cm width, thin skin, easy bruising
  • Proximal muscle weakness, osteoporosis (fractures)
  • Hypertension, hyperglycemia/T2DM, hypokalemia
  • Hirsutism (women), menstrual irregularity, erectile dysfunction
  • Depression, psychosis, insomnia

Investigations

TestFinding
24-hr urine free cortisol↑ (>3x upper limit of normal)
Late-night salivary cortisol↑ (loss of diurnal rhythm)
Overnight 1mg dexamethasone suppressionNo suppression (cortisol >1.8 mcg/dL)
ACTH level↑ (ACTH-dependent) vs ↓ (adrenal)
Pituitary MRIMicroadenoma (Cushing's disease)
High-dose DST (8mg)Suppression in pituitary; NO suppression in ectopic
CRH stimulation↑ in pituitary source
Adrenal CTAdenoma or hyperplasia

Blood Count (CBC)

  • RBC: ↑ Polycythemia (cortisol stimulates erythropoiesis)
  • WBC: ↑ Leukocytosis; neutrophilia + lymphopenia + eosinopenia (classic cortisol effect)
  • Platelets: Normal or elevated

Treatment

CauseTreatment
Pituitary (Cushing's disease)Transsphenoidal surgery (TSS); pasireotide/cabergoline if residual
Adrenal adenomaLaparoscopic adrenalectomy
Ectopic ACTHTreat primary tumor; bilateral adrenalectomy if source not found
ExogenousGradual steroid taper (never abrupt)
Medical bridgeMetyrapone, ketoconazole, mitotane, mifepristone

Nutrition

  • Low-sodium, low-calorie diet
  • High calcium + vitamin D (counter osteoporosis)
  • High protein (counter muscle wasting)

Differential Diagnosis

  • Pseudo-Cushing's (depression, alcoholism, obesity)
  • Metabolic syndrome
  • PCOS (hirsutism, weight gain)
  • Adrenal carcinoma

Contraindications

  • Ketoconazole: hepatotoxicity risk; avoid with hepatic impairment
  • Mitotane: teratogenic; contraception required

6️⃣ ADDISON'S DISEASE (PRIMARY ADRENAL INSUFFICIENCY)

Pathophysiology

Destruction/suppression of adrenal cortex β†’ ↓ cortisol + ↓ aldosterone (↑ ACTH, ↑ MSH β†’ hyperpigmentation)

Age Group

Any age; autoimmune form peaks 30–50 years; tuberculosis-related (developing countries)

Clinical Findings

  • Fatigue, weight loss, anorexia, nausea, vomiting
  • Hyperpigmentation (sun-exposed areas, buccal mucosa, skin creases, scars)
  • Hypotension (especially orthostatic), salt craving
  • Adrenal crisis (Addisonian crisis): Severe hypotension/shock, vomiting, abdominal pain, fever, altered consciousness β€” ICU EMERGENCY

Investigations

TestFinding
Serum cortisol (8 AM)<3 mcg/dL (diagnostic); <18 mcg/dL (suspicious)
ACTH stimulation test (250 mcg)No rise in cortisol (peak <18 mcg/dL)
ACTH level↑↑↑ (primary)
Na⁺↓ Hyponatremia
K⁺↑ Hyperkalemia
Glucose↓ Hypoglycemia
Anti-adrenal antibodies (21-OH)Positive (autoimmune)
Adrenal CTAtrophy (autoimmune); calcification (TB); hemorrhage
DHEA-S↓

Blood Count (CBC)

  • RBC: ↓ Normocytic anemia
  • WBC: ↓ Lymphocytosis + eosinophilia (classic β€” opposite of cortisol excess)
  • Platelets: Normal

Treatment

SettingTreatment
OPD (chronic)Hydrocortisone 15–20 mg/day (AM/PM split) + fludrocortisone 0.05–0.2 mg/day (mineralocorticoid)
Adrenal crisis (ICU)IV hydrocortisone 100 mg bolus then 50–100 mg q6h β†’ IV 0.9% NaCl 1L rapid β†’ glucose correction β†’ treat precipitant
Stress dosingDouble/triple hydrocortisone during illness, surgery, injury
Secondary AIHydrocortisone only (no fludrocortisone needed)

Nutrition

  • Liberal salt diet (especially in hot weather/exercise)
  • High-carbohydrate snacks to prevent hypoglycemia

Differential Diagnosis

  • Septic shock (no hyperpigmentation, normal ACTH)
  • Secondary adrenal insufficiency (pituitary; no hyperpigmentation; ↓ACTH)
  • Hyponatremia from other causes (SIADH, hypothyroidism)

Contraindications

  • Abrupt steroid discontinuation: never β€” precipitates adrenal crisis
  • Rifampicin/anticonvulsants: accelerate cortisol metabolism (increase dose)

7️⃣ CONGENITAL HYPOTHYROIDISM

Pathophysiology

Absent/ectopic/dyshormonogenic thyroid β†’ neonatal T4 deficiency β†’ impaired brain development

Age Group

Neonates (incidence 1:2,000–4,000); F>M

Clinical Findings

  • At birth: often normal (maternal T4 protective)
  • Week 2–4: prolonged neonatal jaundice, poor feeding, hypotonia ("floppy baby"), hoarse cry, large fontanelle, macroglossia, umbilical hernia, mottled/dry skin, hypothermia
  • Untreated β†’ Cretinism: Intellectual disability, short stature, deaf-mutism

Investigations

TestFinding
Newborn screening (heel-prick)↑ TSH or ↓ T4
Confirmatory serum TSH + Free T4↑TSH, ↓FT4
Thyroid ultrasoundAbsence, hypoplasia, ectopia
Thyroid radionuclide scanConfirms ectopia/agenesis
Bone age X-rayDelayed ossification

Blood Count (CBC)

  • RBC: Macrocytic anemia common
  • WBC: Usually normal
  • Platelets: Normal

Treatment

  • Levothyroxine 10–15 mcg/kg/day β€” start within 2 weeks of birth
  • Monitoring: TSH/FT4 every 1–3 months in year 1; normalize TSH within 2 weeks
  • Developmental follow-up essential

Nutrition

  • Breastfeeding encouraged; avoid soy formula (blocks LT4 absorption)
  • Adequate iodine in maternal diet during pregnancy

Contraindications

  • Soy formula concurrent with LT4 β€” reduces absorption significantly

8️⃣ CONGENITAL ADRENAL HYPERPLASIA (CAH)

Pathophysiology

21-hydroxylase deficiency (95% of cases) β†’ impaired cortisol + aldosterone synthesis β†’ ACTH excess β†’ androgen overproduction

Age Group

Neonates (salt-wasting crisis); virilizing form presents later in childhood; non-classic in adolescence/adulthood

Clinical Findings

  • Salt-wasting (neonatal): Vomiting, poor feeding, dehydration, hyponatremia, hyperkalemia, shock (life-threatening Week 1–3)
  • Female virilization: Ambiguous genitalia at birth (clitoromegaly, labial fusion)
  • Males: Normal genitalia but early pubic hair, rapid growth β†’ short stature
  • Non-classic (adolescent/adult): Hirsutism, irregular menses, acne, early pubic hair

Investigations

TestFinding
17-hydroxyprogesterone (17-OHP)↑↑ (>10,000 ng/dL in classic)
Newborn screen↑17-OHP
ACTH stimulationExaggerated 17-OHP rise
Electrolytes↓Na⁺, ↑K⁺ (salt-wasting)
Androstenedione / DHEA-S↑
CYP21A2 gene mutationConfirms diagnosis
Bone ageAdvanced

Blood Count (CBC)

  • RBC: Normal or ↓ (Addisonian anemia component)
  • WBC: ↑ In acute salt-wasting crisis (stress response)
  • Platelets: Normal

Treatment

FormTreatment
Salt-wasting crisis (NICU)IV 0.9% NaCl + glucose + IV hydrocortisone 25 mg/mΒ² bolus
ChronicHydrocortisone 10–15 mg/mΒ²/day (3 doses) + fludrocortisone 0.05–0.2 mg/day
Non-classicLow-dose hydrocortisone or prednisone (if symptomatic)
SurgeryFeminizing genitoplasty in virilized females (timing debated)
Stress dosing3Γ— hydrocortisone during illness/surgery

9️⃣ DIABETES INSIPIDUS (DI)

Pathophysiology

  • Central DI: ↓ADH production (pituitary/hypothalamus damage)
  • Nephrogenic DI: Renal resistance to ADH
  • Result: Massive dilute urine output β†’ hypernatremia

Age Group

Any age; central DI: head trauma/surgery/tumors; nephrogenic: lithium use, genetic (infants)

Clinical Findings

  • Polyuria: 3–20 L/day of dilute urine
  • Polydipsia (if thirst intact) β†’ prevents hypernatremia
  • Hypernatremia/dehydration if unable to access water (unconscious, infants)
  • Nocturia, fatigue

Investigations

TestFinding
Urine osmolality<300 mOsm/kg (inappropriately dilute)
Serum osmolality↑ >295 mOsm/kg
Serum sodium↑ Hypernatremia
Water deprivation testNo urine concentration
Desmopressin (DDAVP) challengeUrine concentrates β†’ Central DI; No response β†’ Nephrogenic DI
Copeptin / plasma ADH↓ (central); Normal/↑ (nephrogenic)
MRI pituitaryLoss of posterior pituitary "bright spot" (central DI)

Blood Count (CBC)

  • RBC: ↑ Hemoconcentration in dehydration
  • WBC: Normal
  • Platelets: Normal

Treatment

TypeTreatment
Central DIDesmopressin (DDAVP) intranasal/oral/IV; treat underlying cause
Nephrogenic DILow-sodium/low-protein diet; thiazide diuretics; indomethacin; discontinue lithium if possible
ICU/AcuteGradual correction of hypernatremia (max 10 mEq/L/day); IV hypotonic fluids
Lithium-inducedAmiloride (protective)

πŸ”Ÿ SYNDROME OF INAPPROPRIATE ADH (SIADH)

Pathophysiology

Excess ADH β†’ water retention β†’ dilutional hyponatremia (euvolemic)

Age Group

Adults, elderly; post-neurosurgery, pneumonia, malignancy (small-cell lung cancer)

Clinical Findings

  • Mild: headache, nausea, fatigue, confusion
  • Severe (Na⁺ <120): seizures, coma, respiratory arrest
  • No edema (euvolemic, not hypovolemic)

Investigations

TestFinding
Serum Na⁺↓ <135 mEq/L
Serum osmolality↓ <275 mOsm/kg
Urine Na⁺↑ >20 mEq/L
Urine osmolality↑ >100 mOsm/kg (inappropriately concentrated)
TSH / cortisolNormal (exclude hypothyroidism/adrenal insufficiency)
CXR / CT chestExclude malignancy/pneumonia

Blood Count (CBC)

  • RBC: ↓ Dilutional (pseudoanemia)
  • WBC: Depends on underlying cause
  • Platelets: Normal or ↓ (dilutional)

Treatment

SeverityTreatment
Mild (Na⁺ 125–135)Fluid restriction 800–1000 mL/day; treat underlying cause
ModerateUrea 15–30g/day orally; vaptans (tolvaptan)
Severe/Symptomatic (ICU)3% hypertonic saline (1–2 mL/kg/hr) β€” correct Na⁺ max 10–12 mEq/L in 24h (avoid osmotic demyelination)

Contraindications

  • Rapid Na⁺ correction >12 mEq/L/day β†’ osmotic demyelination syndrome (ODS)

1️⃣1️⃣ ACROMEGALY

Pathophysiology

Pituitary GH-secreting adenoma β†’ ↑GH β†’ ↑IGF-1 β†’ acral/soft-tissue overgrowth (post-epiphyseal fusion = acromegaly; pre-fusion = gigantism)

Age Group

Adults 30–50 years (mean delay in diagnosis ~10 years)

Clinical Findings

  • Enlargement of hands, feet, jaw (prognathism), nose, tongue
  • Frontal bossing, widened teeth spacing
  • Coarsening facial features, skin thickening
  • Hyperhidrosis, oily skin
  • Carpal tunnel syndrome, arthropathy
  • Hypertension, T2DM, sleep apnea
  • Visual field defects (bitemporal hemianopia β€” chiasm compression)
  • Headache, fatigue

Investigations

TestFinding
IGF-1↑↑ (best screening test)
GH after 75g glucose (OGTT)Fails to suppress to <1 ng/mL
Pituitary MRIMacroadenoma (>1cm, 75%)
Fasting glucose / HbA1cElevated (GH-induced insulin resistance)
Colonoscopy↑ Colorectal polyp/cancer risk
EchocardiogramLVH, cardiomyopathy
Sleep studyObstructive sleep apnea

Blood Count (CBC)

  • RBC: ↑ Polycythemia (GH stimulates erythropoiesis)
  • WBC: Normal
  • Platelets: Normal

Treatment

ModalityDetails
SurgeryTranssphenoidal surgery (first-line; cure rate ~80% for microadenoma)
Somatostatin analoguesOctreotide LAR, lanreotide (medical bridge or adjunct)
GH receptor antagonistPegvisomant (IGF-1 normalisation; not GH)
Dopamine agonistCabergoline (if mixed GH/PRL tumor)
RadiotherapyStereotactic radiosurgery (slow IGF-1 normalisation over years)

Nutrition

  • Low glycemic index diet (insulin resistance management)
  • Calcium + Vitamin D (osteoporosis risk)

1️⃣2️⃣ GIGANTISM

Pathophysiology

GH excess (pituitary adenoma, McCune-Albright syndrome, MEN1, X-LAG syndrome) before epiphyseal closure β†’ excessive linear growth

Age Group

Children and adolescents (before growth plate fusion)

Clinical Findings

  • Height >3 SD above mean for age
  • Large hands/feet, headache, visual changes
  • Delayed puberty (if gonadotropin co-affected)
  • Same metabolic features as acromegaly (hyperglycemia, hypertension)
  • Gigantism + acral features if diagnosed late

Investigations

Same as acromegaly + bone age X-ray (open epiphyses)

Blood Count (CBC)

  • RBC: ↑ (as acromegaly)
  • WBC/Platelets: Normal

Treatment

Same as acromegaly; somatostatin analogues crucial in pediatric patients to preserve growth plates; surgery after puberty if possible

1️⃣3️⃣ PHEOCHROMOCYTOMA

Pathophysiology

Catecholamine (epinephrine, norepinephrine, dopamine)-secreting tumor of adrenal medulla (90%) or extra-adrenal paraganglioma

Age Group

Adults 30–50 years; 10% in children; 10% malignant; 10% bilateral; 10% extra-adrenal (rule of 10s) Associated with MEN2A/2B, VHL, NF1, SDH mutations

Clinical Findings

  • Classic triad: Episodic hypertension + headache + diaphoresis ("spells")
  • Palpitations, pallor, anxiety, tremor
  • Hypertensive crisis provoked by surgery, contrast, stress, drugs (TCA, metoclopramide)
  • Sustained hypertension (50%) or paroxysmal (50%)
  • Weight loss, hyperglycemia

Investigations

TestFinding
24-hr urine metanephrines + catecholamines↑ (sensitivity 98%)
Plasma free metanephrines↑ (best initial test)
CT/MRI adrenalAdrenal mass (>3 cm, heterogeneous, high T2)
ΒΉΒ²Β³I-MIBG scanFunctional uptake (localisation/metastases)
DOTATATE PETSuperior for paraganglioma
Genetic testingSDHx, VHL, RET, NF1 mutations

Blood Count (CBC)

  • RBC: ↑ Polycythemia (EPO stimulation)
  • WBC: ↑ Stress leukocytosis during crisis
  • Platelets: Normal

Treatment

PhaseTreatment
Pre-op Ξ±-blockadePhenoxybenzamine (non-selective Ξ±) 10–14 days minimum, THEN add Ξ²-blocker
SurgeryLaparoscopic adrenalectomy (minimally invasive preferred)
Hypertensive crisis (ICU)IV phentolamine (5–10 mg bolus) or IV nicardipine/nitroprusside
MalignantMIBG therapy, chemotherapy (CVD: cyclophosphamide+vincristine+dacarbazine), sunitinib

Contraindications

  • NEVER give Ξ²-blockers before Ξ±-blockade (paradoxical hypertension β€” unopposed Ξ±-vasoconstriction)
  • Metoclopramide, TCA, dopamine antagonists: can precipitate crisis

1️⃣4️⃣ PRIMARY HYPERALDOSTERONISM (CONN'S SYNDROME)

Pathophysiology

Autonomous aldosterone secretion (unilateral adenoma 35%, bilateral hyperplasia 60%) β†’ ↑Na⁺ retention, ↑K⁺ excretion β†’ hypertension + hypokalemia

Age Group

Adults 30–60; accounts for ~10% of all hypertension (most undiagnosed)

Clinical Findings

  • Resistant hypertension (refractory to 3+ drugs)
  • Hypokalemia: muscle weakness, cramps, palpitations, polyuria/polydipsia (nephrogenic DI-like)
  • Often asymptomatic (K⁺ may be normal in 50%)
  • Headache, fatigue

Investigations

TestFinding
Aldosterone-to-renin ratio (ARR)>30 (with aldosterone >15 ng/dL) β€” screening
Confirmatory: Fludrocortisone suppression / salt loadingAldosterone not suppressed
Adrenal CTAdenoma vs bilateral hyperplasia
Adrenal vein sampling (AVS)Lateralisation (gold standard before surgery)
Serum K⁺↓ (not always)
Plasma renin↓↓ (suppressed)

Blood Count (CBC)

  • RBC: Normal
  • WBC: Normal
  • Platelets: Normal

Treatment

TypeTreatment
Unilateral adenomaLaparoscopic adrenalectomy (curative in >50%)
Bilateral hyperplasiaMineralocorticoid antagonist: spironolactone (first-line) or eplerenone (fewer anti-androgen side effects)
K⁺ replacementPre-op + until surgery

Contraindications

  • Spironolactone: contraindicated in CKD/hyperkalemia (eGFR <30), pregnancy
  • ACE inhibitors/ARBs combined with spironolactone: hyperkalemia risk

1️⃣5️⃣ HYPOPARATHYROIDISM

Pathophysiology

↓PTH β†’ ↓serum Ca²⁺ + ↑serum phosphate β†’ neuromuscular excitability

Age Group

Any age; most common post-thyroid/parathyroid surgery; autoimmune; DiGeorge syndrome (children)

Clinical Findings

  • Tetany: Carpopedal spasm, perioral tingling, laryngospasm, bronchospasm
  • Chvostek sign: Facial twitch on tapping CN VII
  • Trousseau sign: Carpal spasm after BP cuff inflation
  • Seizures (hypocalcemic), QTc prolongation β†’ arrhythmia
  • Cataracts, calcification of basal ganglia, dry skin, brittle nails

Investigations

TestFinding
Serum Ca²⁺↓ <8.5 mg/dL (total); iCa ↓
Serum Phosphate↑
PTH↓ or undetectable
Vitamin D (25-OH)Check level
ECGProlonged QTc
Urine Ca²⁺Normal (distinguish from pseudohypoparathyroidism)

Blood Count (CBC)

  • RBC: Normal
  • WBC: Lymphopenia (DiGeorge syndrome β€” thymic aplasia)
  • Platelets: Normal

Treatment

SettingTreatment
Acute/Severe (ICU)IV calcium gluconate 10% (10 mL over 10 min) β†’ continuous infusion; cardiac monitor
OPD (chronic)Oral calcium carbonate 1–3g/day + active Vitamin D (calcitriol 0.25–2 mcg/day)
DefinitiveRecombinant PTH (teriparatide/Natpara) for refractory cases

Contraindications

  • Thiazide diuretics promote Ca²⁺ reabsorption β€” potentially useful
  • Loop diuretics: worsen hypocalcemia β€” avoid
  • IV calcium too rapidly: cardiac arrest risk (bradycardia/asystole)

1️⃣6️⃣ PRIMARY HYPERPARATHYROIDISM

Pathophysiology

Autonomous PTH secretion (adenoma 80%, hyperplasia 15%, carcinoma <1%) β†’ hypercalcemia

Age Group

Adults >50; F>M (3:1); associated with MEN1, MEN2A, lithium use

Clinical Findings

  • Often asymptomatic (incidental hypercalcemia)
  • Stones (nephrolithiasis), Bones (osteitis fibrosa cystica, fractures), Groans (GI: constipation, PUD, pancreatitis), Psychic moans (depression, cognitive impairment)
  • Hypercalcemic crisis (Ca²⁺ >14 mg/dL): profound weakness, confusion, cardiac arrhythmia, coma β€” ICU

Investigations

TestFinding
Serum Ca²⁺↑
PTH↑ (inappropriate for hypercalcemia)
Phosphate↓
Alkaline phosphatase↑ (bone involvement)
24-hr urine Ca²⁺↑
Technetium sestamibi scanLocalizes adenoma
DEXA bone scanOsteoporosis/osteopenia
Renal USSNephrolithiasis

Blood Count (CBC)

  • RBC: ↑ (mild polycythemia) or normal
  • WBC: Normal
  • Platelets: Normal

Treatment

IndicationTreatment
Symptomatic / Ca²⁺ >1mg/dL above normal / age <50 / T-score <-2.5Parathyroidectomy (surgery)
Asymptomatic surveillanceMonitoring Ca²⁺, PTH, DEXA, renal function annually
MedicalCinacalcet (calcimimetic) β€” reduces PTH; bisphosphonates for osteoporosis
Hypercalcemic crisis (ICU)IV 0.9% NaCl 200–300 mL/hr β†’ furosemide β†’ IV bisphosphonate (zoledronic acid) β†’ calcitonin β†’ dialysis if refractory

Contraindications

  • Thiazides: worsen hypercalcemia β€” avoid
  • Lithium: induces/worsens hyperparathyroidism

1️⃣7️⃣ POLYCYSTIC OVARY SYNDROME (PCOS)

Pathophysiology

LH/FSH imbalance β†’ ↑LH β†’ ↑androgen production by ovarian theca cells + insulin resistance β†’ anovulation, hyperandrogenism, polycystic ovaries

Age Group

Reproductive-age females (15–44 years); most common endocrinopathy in women of reproductive age

Clinical Findings (Rotterdam criteria: 2 of 3)

  1. Oligo/anovulation (irregular periods, infertility)
  2. Clinical/biochemical hyperandrogenism (hirsutism, acne, alopecia, ↑testosterone)
  3. Polycystic ovaries on USS (β‰₯12 follicles per ovary or ovarian volume >10 mL)
  • Metabolic: obesity, insulin resistance, T2DM risk, dyslipidemia
  • Long-term: ↑endometrial cancer risk (anovulatory cycles β†’ unopposed estrogen)
  • Mood disorders, sleep apnea

Investigations

TestFinding
LH:FSH ratio↑ (>2:1, supportive)
Total/free testosterone↑
DHEA-S↑ (mild adrenal androgen)
17-OHP (AM fasting)Normal or mildly ↑ (exclude CAH)
SHBG↓ (increased free testosterone)
Fasting glucose + insulin (HOMA-IR)Insulin resistance
Pelvic USSβ‰₯12 follicles, "pearl necklace" appearance
TSH, prolactinExclude hypothyroidism / hyperprolactinemia

Blood Count (CBC)

  • RBC: Normal or mild ↓ (oligomenorrheic; less blood loss)
  • WBC: Normal or mild ↑ (low-grade inflammation)
  • Platelets: Often ↑ (chronic inflammation/metabolic syndrome association)

Treatment

GoalTreatment
Menstrual regulationCombined OCP (estrogen-progestogen)
HyperandrogenismOCP + spironolactone (anti-androgen); topical eflornithine
Ovulation induction (fertility)Letrozole (first-line); clomiphene; metformin
Insulin resistanceMetformin; lifestyle (weight loss 5–10% restores ovulation)
MetabolicLow-carb diet, exercise, weight loss

Nutrition

  • Low glycemic index diet
  • Weight loss reduces androgen levels and restores menstrual regularity
  • Mediterranean diet (anti-inflammatory)

Contraindications

  • Spironolactone: teratogenic (contraception mandatory); hyperkalemia if K⁺ abnormal
  • OCP: avoid in migraine with aura, thrombophilia, smokers >35

1️⃣8️⃣ PRECOCIOUS PUBERTY

Pathophysiology

  • Central (GnRH-dependent): Premature hypothalamic GnRH β†’ LH/FSH β†’ sex hormone activation; often idiopathic in girls
  • Peripheral (GnRH-independent): Gonadotropin-independent sex hormone secretion (CAH, McCune-Albright, exogenous hormones, gonadal/adrenal tumor)

Age Group

Girls <8 years; Boys <9 years

Clinical Findings

Central: Thelarche, pubarche, menarche (girls); testicular enlargement, pubic hair (boys); advanced bone age; accelerated growth β†’ early epiphyseal fusion β†’ short adult stature
Peripheral: CafΓ©-au-lait spots + fibrous dysplasia (McCune-Albright); asymmetric bone changes

Investigations

TestFinding
Bone age X-rayAdvanced (>2 SD)
LH/FSH baseline↑ (pubertal levels) in central PP
GnRH stimulation testLH >5 IU/L post-stimulation = central PP
Estradiol / Testosterone↑
DHEA-S, 17-OHPElevated if adrenal cause
MRI brainCNS tumor/hamartoma (especially boys)
Pelvic USS / Testicular USSGonadal tumor
Thyroid function (TSH/T4)Severe hypothyroidism can cause precocious puberty

Blood Count (CBC)

  • RBC: ↑ (androgens stimulate erythropoiesis in boys)
  • WBC: Normal
  • Platelets: Normal

Treatment

TypeTreatment
Central PPGnRH agonist (leuprolide, histrelin implant) β€” arrests puberty; restores adult height potential
CAH-relatedTreat CAH (hydrocortisone)
Tumor-relatedSurgery/chemo for gonadal/adrenal tumor
McCune-AlbrightAromatase inhibitors (letrozole) in girls

1️⃣9️⃣ GROWTH HORMONE DEFICIENCY (GHD)

Pathophysiology

↓GH from pituitary (congenital, perinatal insult, tumor, idiopathic) β†’ ↓IGF-1 β†’ reduced linear growth (children) + metabolic effects (adults)

Age Group

  • Children: Short stature, delayed bone age
  • Adults: Post-pituitary adenoma surgery/irradiation; metabolic syndrome phenotype

Clinical Findings

Children: Height <βˆ’2 SD (below 3rd percentile), slow growth velocity (<4 cm/year), chubby body, immature face, micropenis (boys, neonates), hypoglycemia (neonates)
Adults: Increased adiposity (central), reduced lean mass, fatigue, dyslipidemia, reduced bone density, decreased quality of life

Investigations

TestFinding
IGF-1↓ (best screening test)
GH stimulation test (insulin tolerance test or glucagon)GH peak <3–10 ng/mL (criteria vary by assay/age)
MRI pituitaryStructural lesion / empty sella
Bone age X-rayDelayed
IGF-BP3↓
Other pituitary hormonesAssess for panhypopituitarism

Blood Count (CBC)

  • RBC: ↓ Normocytic anemia (GH promotes erythropoiesis)
  • WBC: Normal
  • Platelets: Normal

Treatment

AgeTreatment
ChildrenRecombinant GH (somatropin) 0.025–0.05 mg/kg/day SC; until final height reached
AdultsLower-dose somatropin (0.1–0.4 mg/day) for metabolic benefits
MonitorIGF-1 levels, blood glucose, height velocity, DEXA

Contraindications

  • GH therapy: contraindicated in active malignancy, proliferative diabetic retinopathy, closed epiphyses (children), Prader-Willi with severe obesity/sleep apnea (risk of sudden death)
  • Titrate cautiously in diabetes (can worsen insulin resistance)

2️⃣0️⃣ PROLACTINOMA

Pathophysiology

Benign PRL-secreting pituitary adenoma β†’ ↑prolactin β†’ dopamine inhibition of GnRH β†’ hypogonadism + galactorrhea

Age Group

Young women 20–40 (microadenoma common); men present later with macroadenoma (larger at diagnosis)

Clinical Findings

Women: Amenorrhea, galactorrhea, infertility, low libido, vaginal dryness (hypoestrogen) Men: Erectile dysfunction, low libido, infertility, galactorrhea (rare), gynecomastia Both (Macroadenoma >1cm): Headache, bitemporal hemianopia, cranial nerve palsy, hypopituitarism

Investigations

TestFinding
Serum prolactinMicroadenoma: 100–200 ng/mL; Macroadenoma: >200 ng/mL
Exclude physiological/drug causesPregnancy test, medication review (antipsychotics, metoclopramide, verapamil)
MRI pituitary with contrastAdenoma visualization
Visual field testingBitemporal hemianopia if suprasellar extension
LH/FSH/testosterone/estradiol↓ (hypogonadism)
TSHExclude hypothyroidism (↑ TRH stimulates PRL)

Blood Count (CBC)

  • RBC: ↓ Normocytic anemia (estrogen deficiency in women; testosterone ↓ in men)
  • WBC: Normal
  • Platelets: Normal

Treatment

IndicationTreatment
First-line (medical)Dopamine agonist: Cabergoline (0.5–2 mg twice weekly β€” superior efficacy/tolerability) or Bromocriptine
SurgicalTranssphenoidal surgery if: DA-resistant/intolerant, vision loss, emergency (apoplexy)
RadiotherapyReserved for refractory cases
PregnancyBromocriptine preferred (more safety data); discontinue cabergoline once pregnant (controversial for macroadenomas)

Contraindications

  • Cabergoline: avoid in valvular heart disease (high dose fibrotic risk); use caution in psychiatric disorders
  • Estrogen-only OCP in untreated prolactinoma: controversial (may stimulate growth)

πŸ”¬ CONSOLIDATED CBC / HEMATOLOGY SUMMARY

DiseaseRBCWBCPlateletsKey Pattern
T1DM (DKA)Normal/↓↑ (stress/infection)NormalLeukocytosis in DKA
T2DM↓ (late CKD)NormalNormal/↑
Hypothyroidism↓ MacrocyticNormalMay ↓Macrocytic anemia
Hyperthyroidism↓ (dilutional)↓ Neutropenia (drugs)May ↓Drug-induced agranulocytosis risk
Cushing's↑ Polycythemia↑ Neutrophilia, ↓ Lympho/EosinoNormal/↑Classic cortisol leukogram
Addison's↓ Normocytic↓ Lymphocytosis + EosinophiliaNormalOpposite of Cushing's
Congenital Hypothyroidism↓ MacrocyticNormalNormal
CAHNormal/↓↑ (crisis)Normal
Diabetes Insipidus↑ (hemoconcentration)NormalNormal
SIADH↓ (dilutional)Cause-dependent↓ (dilutional)
Acromegaly↑ PolycythemiaNormalNormal
Gigantism↑NormalNormal
Pheochromocytoma↑ Polycythemia↑ (crisis)NormalParoxysmal
Conn's SyndromeNormalNormalNormal
HypoparathyroidismNormal↓ (DiGeorge)Normal
HyperparathyroidismNormal/↑NormalNormal
PCOSNormal/↓Normal/↑↑Inflammatory pattern
Precocious Puberty↑ (androgens)NormalNormal
GHD↓ NormocyticNormalNormal
Prolactinoma↓ NormocyticNormalNormalHypogonadal anemia

πŸ₯ ICU vs OPD MANAGEMENT GUIDE

ConditionOPDICU Trigger
T1DMRoutine insulin management, HbA1c monitoringDKA (pH <7.3, bicarbonate <15, altered consciousness)
T2DMLifestyle + oral agents/insulinHHS (glucose >600, osmolality >320, no ketones), severe hypoglycemia
HypothyroidismLevothyroxine titrationMyxedema coma (hypothermia, coma, bradycardia)
HyperthyroidismAntithyroid drugs, beta-blockersThyroid storm (HR>140, hyperpyrexia, coma)
Cushing'sBiochemical work-up, surgery schedulingAdrenal crisis post-op, severe infection
Addison'sSteroid replacement, sick-day rulesAdrenal crisis (hypotension, shock, hyponatremia)
CAHHydrocortisone + fludrocortisoneSalt-wasting neonatal crisis
Diabetes InsipidusDDAVP outpatient titrationSevere hypernatremia, unconscious patient
SIADHFluid restriction, treat causeNa⁺ <120 with seizures/coma (hypertonic saline)
PheochromocytomaAlpha-blockade, surgery schedulingHypertensive crisis (phentolamine IV)
HypoparathyroidismOral Ca²⁺ + calcitriolSevere tetany, seizures, QTc prolongation (IV calcium)
HyperparathyroidismSurveillance or cinacalcetHypercalcemic crisis Ca²⁺ >14 mg/dL
ProlactinomaCabergolinePituitary apoplexy (hemorrhage into tumor)

πŸ₯— CONSOLIDATED NUTRITION GUIDE

DiseaseKey Nutritional Focus
T1DM / T2DMCarbohydrate counting; low GI foods; fiber >25g/day; Mediterranean diet
HypothyroidismAdequate iodine; selenium (Hashimoto's); take LT4 before food
HyperthyroidismHigh-calorie/protein; avoid excess iodine; Ca²⁺ + Vit D post-surgery
Cushing's SyndromeLow sodium; high Ca²⁺ + Vit D; high protein (anti-catabolic)
Addison's DiseaseLiberal salt; high-carb snacks; extra salt in heat/exercise
CAHSalt supplementation in salt-wasting form; balanced growth calories
AcromegalyLow GI (insulin resistance); Ca²⁺ + Vit D
PCOSLow GI; Mediterranean diet; weight loss (5–10%)
HypoparathyroidismHigh calcium diet (dairy); Vit D; low-phosphate diet
HyperparathyroidismAdequate (NOT restricted) calcium; hydration; low-oxalate diet
GHDAdequate protein and calories for growth (children); balanced adult diet

⚠️ KEY CONTRAINDICATIONS SUMMARY

Drug/TreatmentContraindicated In
MetformineGFR <30, IV contrast (hold 48h), T1DM monotherapy, liver failure
SGLT-2iT1DM (euDKA), eGFR <20, recurrent UTI/genital fungal infections
GLP-1 agonistsPersonal/family history medullary thyroid cancer, MEN2
Methimazole1st trimester pregnancy (use PTU)
RAI (ΒΉΒ³ΒΉI)Pregnancy, breastfeeding, active Graves' ophthalmopathy
Beta-blocker in pheoBefore alpha-blockade (paradoxical hypertension)
Loop diureticsHypoparathyroidism / hypocalcemia (worsens)
ThiazidesHypercalcemia / hyperparathyroidism (worsens)
Rapid Na⁺ correctionSIADH (>12 mEq/L/day β†’ osmotic demyelination syndrome)
Levothyroxine aloneUntreated adrenal insufficiency (precipitates adrenal crisis)
SpironolactoneCKD/hyperkalemia, pregnancy
GH therapyActive malignancy, closed epiphyses, severe Prader-Willi
Cabergoline high-dosePre-existing valvular heart disease
IV calcium bolus fastCardiac arrest risk β€” always infuse slowly on monitor

πŸ” DIFFERENTIAL DIAGNOSIS FLOWCHART

HYPERTENSION (resistant)
β”œβ”€β”€ + Hypokalemia β†’ PRIMARY HYPERALDOSTERONISM (Conn's)
β”œβ”€β”€ + Spells, sweating, headache β†’ PHEOCHROMOCYTOMA
β”œβ”€β”€ + Moon face, striae, obesity β†’ CUSHING'S SYNDROME
└── + Sleep apnea β†’ ACROMEGALY

AMENORRHEA + GALACTORRHEA
β”œβ”€β”€ + ↑ Prolactin + MRI adenoma β†’ PROLACTINOMA
β”œβ”€β”€ + TSH ↑ β†’ HYPOTHYROIDISM
└── + LH:FSH ↑ + USS polycystic β†’ PCOS

HYPOGLYCEMIA
β”œβ”€β”€ Neonatal + salt-wasting β†’ CAH or ADDISON'S
β”œβ”€β”€ + Insulinoma features β†’ Insulinoma (separate entity)
└── + Poor feeding, hypotonia, neonate β†’ CONGENITAL HYPOTHYROIDISM / GHD

POLYURIA + POLYDIPSIA
β”œβ”€β”€ Glucose ↑ β†’ DM (T1 or T2)
β”œβ”€β”€ Glucose normal + dilute urine + Na⁺ ↑ β†’ DIABETES INSIPIDUS
β”œβ”€β”€ Glucose normal + hypokalemia + HTN β†’ CONN'S SYNDROME
└── Ca²⁺ ↑ β†’ HYPERPARATHYROIDISM

TALL STATURE (child) + LARGE HANDS/FEET
└── ↑ IGF-1 + ↑ GH β†’ GIGANTISM

SHORT STATURE (child)
β”œβ”€β”€ ↓ IGF-1 + ↓ GH stimulation β†’ GHD
└── ↑ TSH + ↓ FT4 β†’ HYPOTHYROIDISM

πŸ“Š DIAGNOSTIC FLOW SUMMARY (QUICK REFERENCE)

Symptom/SignFirst TestConfirms
Hyperglycemia, polyuriaFasting glucose, HbA1cDM type (C-peptide, autoantibodies)
Weight gain, cold intoleranceTSHHypothyroidism
Weight loss, tremor, palpitationsTSH (suppressed) + FT4Hyperthyroidism
Hyperpigmentation + hypotension8AM cortisol β†’ ACTH stimAddison's disease
Moon face + purple striae24h UFC β†’ ACTHCushing's syndrome
Episodic HTN + headache + sweatingPlasma metanephrinesPheochromocytoma
Resistant HTN + hypokalemiaAldosterone:Renin ratioConn's syndrome
Tetany + perioral tinglingSerum calcium + PTHHypoparathyroidism
Hypercalcemia + kidney stonesSerum Ca²⁺ + PTHHyperparathyroidism
Amenorrhea + galactorrheaProlactin + MRIProlactinoma
Polycystic ovaries + hirsutismLH/FSH + testosterone + USSPCOS
Excessive height + large acralIGF-1 + OGTT-GHGigantism/Acromegaly
Short stature + slow growthIGF-1 + GH stimulation testGHD
Early puberty in childBone age + GnRH stimulationPrecocious Puberty
Massive dilute polyuria (normal glucose)Urine osmolality + water deprivationDiabetes Insipidus
Hyponatremia + euvolemicUrine Na⁺ + urine OsmSIADH
Prolonged neonatal jaundice + floppyTSH + FT4 neonatal screenCongenital hypothyroidism
Neonatal salt-wasting + ambiguous genitalia17-OHP + electrolytesCAH

Sources: Goldman-Cecil Medicine; Costanzo Physiology 7e; Katzung's Basic & Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics; Tietz Textbook of Laboratory Medicine 7e; Miller's Anesthesia 10e; Sabiston Textbook of Surgery; Family Medicine 9e. Compiled April 2026.
---Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.